Literature DB >> 12124845

Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells.

Keding Cheng1, Razelle Kurzrock, Xiangguo Qiu, Zeev Estrov, Stella Ku, Kim M Dulski, Jean Y J Wang, Moshe Talpaz.   

Abstract

BACKGROUND: BCR-ABL formation is critical to oncogenic transformation in chronic myelogenous leukemia and has been implicated as a key event leading to alterations in cytoskeletal structures and adhesion in the leukemic cells. The authors therefore investigated the effect of p210(BCR-ABL) on actin polymerization as well as on the expression and phosphorylation state of the adhesion proteins paxillin and focal adhesion kinase (FAK).
METHODS: Transfection with BCR-ABL constructs abrogated the ability of NIH 3T3 fibroblasts to adhere and the cells underwent striking morphologic changes.
RESULTS: Scanning electron microscopy revealed that the cells lost their elongated appearance and became rounded. This alteration was associated with significantly reduced actin polymerization. In addition, steady-state levels of paxillin and FAK protein were increased. However, while the overall level of phosphotyrosines was also increased, the amount of tyrosine phosphorylated paxillin and FAK was reduced in the BCR-ABL-transfected cells as compared to the parental cells. Culture on extracellular fibronectin matrix partially reversed the morphologic changes and resulted in a return, albeit incomplete, of filamentous actin in BCR-ABL-transfected 3T3 fibroblasts. In addition, phosphorylation of paxillin and FAK in the BCR-ABL-transfected NIH 3T3 cells was restored.
CONCLUSIONS: The authors conclude that, in the current system, transfection of BCR-ABL attenuates FAK and paxillin phosphorylation and reduces actin polymerization, events accompanied by significant alterations in cellular morphology. The observation that exposure of the cells to fibronectin partially reverses all these changes suggests that the focal adhesion proteins and actin structures nevertheless remain responsive to signaling from the outside. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10670

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124845     DOI: 10.1002/cncr.10670

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.

Authors:  Chiara Ambrogio; Claudia Voena; Andrea D Manazza; Roberto Piva; Ludovica Riera; Laura Barberis; Carlotta Costa; Guido Tarone; Paola Defilippi; Emilio Hirsch; Elisabetta Boeri Erba; Shabaz Mohammed; Ole N Jensen; Giorgio Palestro; Giorgio Inghirami; Roberto Chiarle
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

Review 2.  Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses.

Authors:  Ingo Roeder; Ingmar Glauche
Journal:  J Mol Med (Berl)       Date:  2007-07-28       Impact factor: 4.599

Review 3.  Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.

Authors:  Mohamed A M Ali
Journal:  Mol Diagn Ther       Date:  2016-08       Impact factor: 4.074

4.  The HCMV gH/gL/UL128-131 complex triggers the specific cellular activation required for efficient viral internalization into target monocytes.

Authors:  Maciej T Nogalski; Gary C T Chan; Emily V Stevenson; Donna K Collins-McMillen; Andrew D Yurochko
Journal:  PLoS Pathog       Date:  2013-07-11       Impact factor: 6.823

5.  Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia.

Authors:  Rahul Kumar; Raquel S Pereira; Costanza Zanetti; Valentina R Minciacchi; Maximilian Merten; Melanie Meister; Julian Niemann; Marina S Dietz; Nina Rüssel; Frank Schnütgen; Minori Tamai; Koshi Akahane; Takeshi Inukai; Thomas Oellerich; Hans Michael Kvasnicka; Heike Pfeifer; Franck E Nicolini; Mike Heilemann; Richard A Van Etten; Daniela S Krause
Journal:  Leukemia       Date:  2020-05-21       Impact factor: 11.528

6.  Comparative Characterization of Osteoclasts Derived From Murine Bone Marrow Macrophages and RAW 264.7 Cells Using Quantitative Proteomics.

Authors:  Andrew Yh Ng; Chengjian Tu; Shichen Shen; Ding Xu; Merry J Oursler; Jun Qu; Shuying Yang
Journal:  JBMR Plus       Date:  2018-07-07

7.  Expression of Paxillin is Correlated with Clinical Prognosis in Colorectal Cancer Patients.

Authors:  Cheng-jin Zhao; Shuang-kuan Du; Xing-bo Dang; Min Gong
Journal:  Med Sci Monit       Date:  2015-07-10

Review 8.  Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors:  Abdulaziz B Hamid; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.